Alzamend Neuro, Inc. · NASDAQ:ALZN
Alzamend Neuro — IPO Roadshow (June 2021)
20 slides from Alzamend Neuro's IPO roadshow presentation, Jun 7, 2021
Slide 1: Alzamend Neuro, Inc. June 2021 Free Writing Prospectus
1 Alzamend Neuro, Inc. June 2021 Filed Pursuant to Rule 433 Issuer Free Writing Prospectus Registration Statement File No. 333-255955 FREE WRITING PROSPECTUS STATEMENT This presentation highlights basic information about us and the offering to which this presentation relates. Because it is a summary
Slide 2: Cautionary Note Regarding Forward-Looking Statements
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS 3 Certain statements in this presentation may constitute “forward-looking statements” within the meaning of the Private Litigation Securities Litigation Reform Act of 1995. Those statements include, but are not limited to, statements with respect
Slide 3: Table of Contents
TABLE OF CONTENTS 4 Introduction Company Overview 5 Overview of Alzheimer’s Disease Alzheimer’s Disease (“AD”) 6 Economic Burden 7 Therapeutic Landscape 8 Our Science General Scientific Overview 9 AL001 (LiProSal™) 10-12 AL002 (CAO22W) 13 Specific Details Intellectual Property (Licensed Patents) 14
Slide 4: Company Overview
Alzamend Neuro, Inc. information cannot be disclosed or reprinted without prior written permission. Company Overview INTRODUCTION Company history Current projects 5 AL001 (aka LiProSal): • an ionic cocrystal of lithium for the treatment of Alzheimer’s Disease and other neurodegenerative diseases and
Slide 5: Overview of Alzheimer's Disease
Alzamend Neuro, Inc. information cannot be disclosed or reprinted without prior written permission. Alzheimer’s Disease OVERVIEW OF ALZHEIMER’S DISEASE 6 Alzheimer’s Disease: Alzheimer’s Disease is an irreversible, progressive brain disorder that slowly destroys memory and cognitive skills, and even
Slide 6: Economic Burden
Alzamend Neuro, Inc. information cannot be disclosed or reprinted without prior written permission. Economic Burden 1. In 2021, the estimated healthcare costs for treating individuals with Alzheimer’s Disease in the United States will be $355 billion, including $239 billion in Medicare and Medicaid
Slide 7: Therapeutic Landscape
Alzamend Neuro, Inc. information cannot be disclosed or reprinted without prior written permission. Therapeutic Landscape 8 https://alz-journals.onlinelibrary.wiley.com/cms/asset/006b182a-0807-477d-99bd-45d8c5306665/trc212050-gra-0001-m.jpg OVERVIEW OF ALZHEIMER’S DISEASE
Slide 8: General Scientific Overview
Alzamend Neuro, Inc. information cannot be disclosed or reprinted without prior written permission. General Scientific Overview OUR SCIENCE 9 *IND – Investigational New Drug **There is no guarantee that the FDA will approve any IND Submission
Slide 9: AL001 (LiProSal)
Alzamend Neuro, Inc. information cannot be disclosed or reprinted without prior written permission. AL001 (LiProSal) 10 • AL001 is a patented ionic cocrystal technology delivering a therapeutic combination of lithium, proline and salicylate • AL001 exhibits improved nonclinical pharmacokinetics and
Slide 10: AL001 (LiProSal) Preclinical Results
Alzamend Neuro, Inc. information cannot be disclosed or reprinted without prior written permission. AL001 (LiProSal) 11 The results of our preclinical studies, conducted from May 2016 to June 2017, are summarized below: • AL001 had no effect on renal COX2 activity (Tg-Ctrl vs. AL001: p > 0.05), a bi
Slide 11: AL001 (LiProSal) Preclinical Study Design
Alzamend Neuro, Inc. information cannot be disclosed or reprinted without prior written permission. AL001 (LiProSal) 12 • Our preclinical studies encompassed the treatment of 28 transgenic (or genetically modified) and 10 non-transgenic mice with lithium carbonate and AL001. • Female APPSWE/PS1dE9 m
Slide 12: AL002 (CAO22W)
Alzamend Neuro, Inc. information cannot be disclosed or reprinted without prior written permission. AL002 (CAO22W) 13 OUR SCIENCE A cell-based therapeutic vaccine which seeks to restore the ability of the patient’s immunological system to combat Alzheimer’s Disease beta-amyloid plaques Hypothesis: ▪
Slide 13: Intellectual Property (Licensed Patents)
Alzamend Neuro, Inc. information cannot be disclosed or reprinted without prior written permission. Intellectual Property (Licensed Patents) SPECIFIC DETAILS 14 Title of Patent Patent Type Therapeutic Drug Date Filed Date Issued Expiration Date Application/Patent # Lithium Cocrystals and an Addition
Slide 14: Recent IPOs of Biotechnology Companies with AD Indication
Alzamend Neuro, Inc. information cannot be disclosed or reprinted without prior written permission. Recent IPOs of Biotechnology Companies with AD Indication 15 Company Science/ Treatment Use of Funds Employees IPO Date IPO Price IPO Proceeds Total Shares IPO Valuation Athira Pharma Alzheimer’s + Ne
Slide 15: Use of Proceeds
Alzamend Neuro, Inc. information cannot be disclosed or reprinted without prior written permission. Use of Proceeds 16 *Clinical Trial estimates vary depending on specific requirements from the FDA (Post IND). Description Amount Over-allotment Phase I Clinical Trials for AL001 $5,300,000 $5,300,000
Slide 16: IPO Terms
Alzamend Neuro, Inc. information cannot be disclosed or reprinted without prior written permission. IPO Terms 17 Description Amount Over-allotment Total offering $12,500,000 $14,375,000 Price per share $5.00 $5.00 Number of shares 2,500,000 2,875,000 Shares outstanding 67,429,525 67,429,525 Conversi
Slide 17: Alzamend Leadership Team
Alzamend Neuro, Inc. information cannot be disclosed or reprinted without prior written permission. Alzamend Leadership Team ALZAMEND NEURO 18 Stephan Jackman Chief Executive Officer and Director 20+ years multi-industry experience, specialized in Biotech and Pharmaceutical Lien T. Escalona Chief Fi
Slide 18: Alzamend Board of Directors
Alzamend Neuro, Inc. information cannot be disclosed or reprinted without prior written permission. Alzamend Board of Directors 19 Lynne Fahey McGrath Regulatory Affairs and Product Development Consultant 30+ years experience, Biotech and Pharmaceuticals M.P.H./Ph.D., Public Health from UMDNJ – Robe
Slide 19: Alzamend Scientific Advisory Board
Alzamend Neuro, Inc. information cannot be disclosed or reprinted without prior written permission. Alzamend Scientific Advisory Board 20 Eric McDade, DO Associate Director of the Dominantly Inherited Alzheimer Network Trials Unit (“DIAN-TU”), Washington University School of Medicine 76+ Peer-Review
Slide 20: For more information please contact
21 For more information please contact: Stephan Jackman Chief Executive Officer June 2021 Filed Pursuant to Rule 433 Issuer Free Writing Prospectus Registration Statement File No. 333-255955